Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cognitive Profile of Patients with Late-Onset Unexplained Epilepsy
Aging, Dementia, and Behavioral Neurology
Aging and Dementia Posters (7:00 AM-5:00 PM)
076
To characterize the cognitive profile of patients with late-onset unexplained epilepsy (LOUE)

Approximately 25-50% of epilepsy cases with elderly-onset do not have a clear etiology. Large database studies have identified LOUE as a risk factor for dementia, however the cognitive profile and trajectory of LOUE have not been well-described.

Patients were recruited from Brigham and Women’s Hospital and affiliated hospitals. Inclusion criteria: new onset seizures >60yo, onset <3 years, absence of cortical lesions on MRI and of provoking factors. Patients underwent the Clinical Dementia Rating (CDR) Scale and a neuropsychological battery to assess 4 cognitive domains: global cognition (Preclinical Alzheimer Cognitive Composite), delayed verbal recall (Free and Cued Selective Reminding Test and Logical Memory), processing speed (Trailmaking Test A, Digit Symbol Substitution Test), and executive function (Trailmaking Test B and Controlled Oral Word Association Test). Performances were normalized to generate z-scores.

We enrolled 25 patients. Mean (+SD) age was 69 ± 5.79 years and educational years was 18 ± 2.16 years. 44% were male. Global CDR scores were 0.0 (n=17) and 0.5 (n=8); CDR sum-of-boxes ranged from 0.0-3.5. Ambulatory EEG findings included bi-temporal (n=9), left-temporal (n=9), and right-temporal (n=3) epileptiform abnormalities, and normal EEG (n=4). 17 subjects were on antiseizure medicine monotherapy. The mean z-score for global cognition was -0.51 (range 3.75, 1.01), delayed verbal recall -0.74 (-3.64, 1.17), processing speed -0.37 (-6.45, 1.67), and executive function -1.055 (range, -7.78, 1.67).

Patients with LOUE exhibit mild deficits across multiple cognitive domains around the time of epilepsy diagnosis. Our future directions include characterization of the underlying factors and the natural history of LOUE.

Authors/Disclosures
Mallika Purandare (Brigham and Women's Hospital)
PRESENTER
Mallika Purandare has nothing to disclose.
Mallika Purandare (Brigham and Women's Hospital) Mallika Purandare has nothing to disclose.
Page B. Pennell, MD, FÂé¶¹´«Ã½Ó³»­ (University of Pittsburgh School of Medicine) The institution of Dr. Pennell has received research support from NIH.
Gad Marshall, MD (Brigham and Women's Hospital) Dr. Marshall has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Pharma USA Inc. Dr. Marshall has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Beth Israel Deaconness Medical Center. Dr. Marshall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Harvard Health Publications.
Rani A. Sarkis, MD, MSc (Brigham and Women'S) The institution of Dr. Sarkis has received research support from NINDS.